Delivery Order SPE2DB20D1100-SPE2DB25FE1F9
- Not listed
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 ml pens. The contract, which carries a firm fixed price structure with no set-aside designation, is scheduled for completion by August 12, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 ml pen injectors, valued at $2,343.59, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. The contract is performed from the company's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of September 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The pharmaceutical products will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency awarded a $2,343.59 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Tezspire 210 mg/1.91 mL pens. The contract, which is scheduled for completion by September 16, 2025, carries no set-aside designation and represents a competitively awarded transaction. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency awarded a $9,374.36 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pens on July 25, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order is unset-aside and competitively awarded, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a monoclonal antibody biologic used in asthma and chronic rhinosinusitis treatment, representing part of...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectables. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion deadline of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $28,123.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract, with an ultimate completion date of September 10, 2025, represents a non-set-aside competitive award executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors with an ultimate completion date of September 11, 2025. This competitive award was issued under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with completion targeted for August 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a $9,374.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors on August 7, 2025, with an ultimate completion date of August 28, 2025. This non-set-aside contract is being performed at the company's corporate headquarters in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in respiratory therapy, reflecting the Defense Logistics Agency's continued procurement of specialized...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1F9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen units, with an ultimate completion date of September 9, 2025. This is a firm fixed price delivery order issued on August 18, 2025, with no set-aside designation, indicating the award was made through open and competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Tezspire, a specialty biologic medication, represents the type of specialized pharmaceutical commodity that DLA procures through its structured vendor relationships to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.4k | 8/18/25 |